Researchers at New York University (NYU) have engineered a 3D printed model that recreates the nutrient-deprived conditions fostering cancer spread, or metastasis. Published in Life Science Alliance, this breakthrough model enables the direct observation of metastatic behavior in real-time, providing researchers with unprecedented insights into a critical stage in cancer progression often hidden in live patients and traditional models.Design and implementation of a metabolic microenvironment chamber for 3D cultures. Photo via NYU.Metastasisthe movement of cancer cells from the primary site to other organsaccounts for most cancer-related fatalities. While advancements in cancer treatment have improved overall prognoses, metastasis presents persistent challenges. NYUs 3D microenvironment chamber, known as 3MIC, uses live microscopy to capture how cancer cells acquire metastatic traits within oxygen-deprived, low-nutrient zones deep within tumors. Carlos Carmona-Fontaine, an associate professor at NYU and the studys lead author, highlights this step as a critical frontier in cancer research. Witnessing the transition of a tumor cell to a metastatic state could be transformative, he noted, underscoring the difficulty of observing such events in conventional models.Using precisely engineered geometry, 3MIC illuminates cancers behavior in extreme conditions, where resources are scarce and traditional treatments often fail. Carmona-Fontaines team noted that established therapies like Taxol, effective under normal conditions, showed limited efficacy in targeting cancer cells deprived of nutrients and oxygen. This discovery suggests that the diminished response to drugs in metastatic cancers may result from cellular adaptations rather than reduced drug access.Time-lapse of Cancer Cell Behavior Under Different Conditions. Photo via NYU.Developments in 3D Printed Tumor ResearchIn 2023,CELLINK collaborated with Carcinotech to advance cancer drug development using 3D printed tumor models. This partnership focuses on developing and commercializing protocols for biofabricating 3D printed tumor models using various cancer cell lines. By leveraging CELLINKs BIO CELLX system, the collaboration aims to enhance the accuracy and speed of drug testing processes, thereby reducing development costs and improving research outcomes. The protocols developed are designed to incorporate a physiologically representative ratio of five key cell types relevant to each cancer type, ensuring that the models accurately reflect the tumor microenvironment.Additionally, researchers at Tel Aviv University developed a 3D printed glioblastoma model using patient-derived cells to create personalized tumor environments. This model represents the first fully functioning 3D replica of a glioblastoma tumor, including the surrounding tissues that influence its development. By enabling the creation of 100 tiny tumors from a single patient sample, the model facilitates the rapid screening of multiple drug combinations to identify the most effective treatments. Additionally, the TAU team used this technology to target specific protein mechanisms that contribute to immune system-mediated tumor spread, successfully delaying glioblastoma growth and inhibiting its progression.CELLINK BIO CELLX 3D biodispenser. Photo via CELLINK.Your voice matters in the 2024 3D Printing Industry Awards. Vote Now!What will the future of 3D printing look like?Which recent trends are driving the 3D printing industry, as highlighted by experts?Subscribe to the 3D Printing Industry newsletter to stay updated with the latest news and insights.Stay connected with the latest in 3D printing by following us on Twitter and Facebook, and dont forget to subscribe to the 3D Printing Industry YouTube channel for more exclusive content.Featured Images showcase the Design and implementation of a metabolic microenvironment chamber for 3D cultures and a Time-lapse of Cancer Cell Behavior Under Different Conditions. Photos via NYU.